Precision Targeting of Cancer Chemotherapy Using Non-Invasive Focused Resonance Nano-Permeabilization (FORN): Enhancing Drug
Delivery to Limit Life-Threatening Systemic Toxicities and Eliciting Good Clinical Outcomes
Meena Augustus, Anjana Rani Nair,
Gopalapillai Sreedharan Nayar, Rajah
Correspondence Address :
CEO & CSO, Shreis Scalene Therapeutics LLC Gaithersburg
Tel: +1 240 481 6007
Received on: September 13, 2017, Accepted on: October 11, 2017, Published on: October 17, 2017
Citation: Meena Augustus, Anjana Rani Nair, Gopalapillai Sreedharan Nayar, Rajah Vijay Kumar (2017). Precision Targeting of Cancer Chemotherapy
Using Non-Invasive Focused Resonance Nano-Permeabilization (FORN): Enhancing Drug Delivery to Limit Life-Threatening Systemic
Toxicities and Eliciting Good Clinical Outcomes
Copyright: 2017 Meena Augustus, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Focused Resonance Nano-permeabilization (FORN) (US Patent 9,616, 245 B2-Apr 11th 2017) enables the 'targeted' delivery of chemo-therapeutic molecules using a safe, non-invasive, whole-body therapeutic device. The prototype device houses a gantry with specialized, near field, radio-frequency (RF) antennae and guns to deliver instantaneous, magnetic resonance. Drug focusing and delivery was enabled using FORN in a patient with advanced, loco-regionally recurrent, metastatic, nasopharyngeal carcinoma (NPC). Nonionizing, safe, extraneous-source radio-frequencies (RF) were delivered in the presence of an instantaneous magnetic field, to create temporary drug molecular weight-specific nanopores in the cell membrane of target lesions, concurrently with systemic chemotherapy. The high frequency RF is timed and delivered to regions of interest (ROIs) to span peak plasma concentrations of infused chemotherapeutic drugs over multiple treatment cycles. FORN-enabled chemotherapy-related adverse event evaluation and tumor response based on PERCIST 1.0 reflected improved clinical, anatomical and metabolic outcomes and significantly reduced myelosuppression in the patient who received 6+1 Cycles of combination chemotherapy, over an extended period of time. Functional Assessment of Cancer Treatment-Head & Neck (FACT-H&N) / Quality of Life (QoL) and Karnofsky Performance Status (KPS) reflected overall patient well-being. Recurrent, loco-regional disease, nodal, hepatic and skeletal metastases showed dramatic response on PET-CT follow up. Concurrent chemo-radiotherapy (CCRT) as a treatment paradigm is the standard of practice in locally advanced nasopharyngeal carcinoma (NPC). Different chemotherapy regimens used in relapsed NPC with distant metastases, very often fail any attempts to treat or palliate. The severe cytotoxicity experienced with 'standard of care' palliative chemotherapy in end-stage disease has made patient compliance poor and survival statistics dismal. The role of concurrent chemotherapy with a drug focusing and delivery-enabling technology like FORN can help overcome dose-limiting cytotoxicity and improve therapeutic windows with existing and emerging chemotherapeutic regimens. Providing effective palliation that is largely lacking - while positively impacting therapeutic outcomes and progression free survival - fills a very large vacuum and unmet, urgent medical need today.
Keywords: Focused resonance nano-permeabilization, Non-invasive targeted cancer drug delivery, Therapeutic device, Chemotherapy-related systemic toxicity, Effective palliation and clinical response